2025年4月30日，美国加州北区法院就Epic Games 与苹果公司围绕"苹果税"的法律纠纷做出了一项具有里程 碑意义的裁决：苹果 "故意违反"了2021年禁止该公司实施反竞争定价的禁令，为此，苹果必须停止从苹果商 店以外的应用销售中抽取27%的佣金，并不得限制开发人员使用链接、按钮或行动号召的设计或放置来引导 用户使用其他付款方式的能力，或对如此做的开发者进行报复。 也就是说，美国开发者可以在苹果系统上将用户引导到外部网站进行交易，而无需支付15-30%的"苹果税"。 这项裁决不仅有利于Epic Games，而且对世界各地的开发者来说都是一次难得的胜利——开发商现在拥有了 前所未有的自由。 作为回应，苹果公司虽然更新了其美国的应用审核指南，但很快就在5月5日向美国第九巡回上诉法院提交了 上诉通知。 自2020年以来，Epic Games与苹果公司就应用商店规则、垄断指控和开发者权利展开了激烈的争斗，如今已 演变成科技史上最大的法律纠纷之一。近五年的庭审中，苹果赢得了许多辩论并一直处于上风。但这一次裁 决是Epic Games首次获得的"重大胜利"，其结果或将对全球数字市场运作产生更广泛的影响。 一、内部 ...

此外，苹果公司还在测试Safari 18浏览器的新功能，包括"智能搜索"和"网页橡皮擦"。 其中，"智能搜索"可以利用苹果的设备端人工智能技术（特别是 Ajax 语言学习模型）来识别网页中的 主题和关键词，并以此为基础进行内容总结。在选择关键词时，苹果的LLM 软件会识别句子中提供解 释或描述物体结构的部分（具体取决于文本内容）。文本中重复出现的词语和关键句子会被识别为文本 主题。 而"网页橡皮擦"则允许用户删除网页上的特定内容，如广告或图像。该功能预计将建立在Safari现有的 隐私保护功能之上，允许用户从他们选择的任何网页中删除不需要的内容。 苹果的分析师评价称，对于标志性的iPhone和拥有超过 20 亿活跃设备的苹果公司来说，这场即将到来 的转变意义重大。自2007年推出第一款苹果智能手机以来，用户一直通过谷歌搜索来浏览网页。现在， 苹果的用户将进入一个由多家公司主导的人工智能世界。 美国东部时间5月7日晚，中美两国最大的搜索应用公司百度和谷歌，突然上演了股价"大跳水"。 截至美股收盘，谷歌母公司Alphabet的股价暴跌了7.6%，市值蒸发超过1500亿美元（约人民币1.08万亿 元）。同时，百度当 ...

电影工业的全球化导致美国电影行业中大量的工作机会、地方税收、旅游产业外流。 而作为"政治正确"的引领者，近几年奥斯卡的每次颁奖都像是在往保守主义者的伤口上撒盐。 美国总统唐纳德·特朗普日前宣布，将对所有非美国制作的电影征收100%的关税。 尽管这关税看上去像是在无差别征收，但实际上板子精准地打在了好莱坞的屁股上。 有网友总结，按照这个标准，被征收的对象包括但不限于： 好莱坞大片基本上被一网打尽。 对于特朗普来说，好莱坞属于在经济和意识形态两个方面给他添堵。 《碟中谍8》（英国）； 《超人》（挪威、美国）； 《侏罗纪世界4》（英国、泰国、美国）； 《神奇四侠：初露锋芒》（英国、西班牙）； 《阿凡达3》（新西兰）； 《复仇者联盟5》（英国）； 《奥德赛》（希腊、意大利、英国）； 《蜘蛛侠4》（英国）； 《沙丘：救世主》（匈牙利）； 和所有全球化的产业一样，好莱坞也吃尽了比较优势的红利。 在美国本土拍电影，人工和税收成本都很高。 当年陈思诚在纽约拍摄《唐探2》，就感受到了美国的人工成本之高，光是一名充当背景的群众演员， 薪酬就达到将近2000元人民币一天。 所以后来陈思诚拍《唐探1900》，干脆在国内搭了一个"旧金 ...

Core Insights - Meta executives acknowledge that TikTok is significantly outperforming Facebook and Instagram, with CEO Mark Zuckerberg describing Facebook as a "challenger" that has "lost momentum" [2][4] - TikTok's ability to create a shared contextual experience among users is highlighted as a key competitive advantage, allowing friends to see similar content without needing to share it directly [4] - Meta's internal discussions reveal concerns about competition from TikTok and other platforms, indicating a shift in the social media landscape where user engagement time is increasingly dominated by TikTok [3][5] Group 1: Meta's Competitive Position - Meta executives, including Zuckerberg and Instagram head Adam Mosseri, view TikTok as a major threat, with Mosseri predicting TikTok will surpass YouTube in user engagement [2][3] - Despite Facebook having the largest number of daily and weekly active users, it no longer leads in user engagement time, with TikTok taking the lead [4] - The internal documents suggest that Meta is struggling to maintain its position in a highly competitive market, with various companies eroding its growth potential [5] Group 2: User Engagement Trends - Research indicates that TikTok users, particularly those aged 4 to 18, spend 60% more time on TikTok than on YouTube, highlighting a shift in user preferences [2] - TikTok's introduction of 60-minute video uploads is seen as a direct challenge to YouTube, further intensifying competition in the video content space [2] - Meta executives recognize that merely adding new features is insufficient to retain users, as they face competition from a variety of popular social applications [5]

【环球网科技综合报道】5月8日消息，据路透社报道，苹果公司近日向美国北加州地方法院提出紧急动议，请求暂停执行针对其App Store的新规则，这一 举动再次将苹果公司置于反垄断争议的风口浪尖。 此前，美国联邦法官Yvonne Gonzalez Rogers于5月1日作出裁定，认定苹果公司违反了2021年法院命令，未能在App Store中开放外部支付选项，构成反竞争 行为。法官指出，苹果不仅未能遵守命令，反而设计新的反竞争措施，意图维持其高利润的30%应用内购买抽佣模式。尽管苹果随后允许开发者引导用户通 过网页完成应用内购买交易，但仍强收27%的佣金。 5月2日，苹果更新了美国地区的App Store规则，不再限制开发者添加按钮、外部链接或其他行动号召，表面上看似允许开发者绕过30%的抽佣机制。然而， 这一变化并未平息争议，反而引发了更多质疑。裁决生效后，包括Kindle、Patreon和Spotify在内的多家知名应用迅速调整策略，在美国市场内启用外部支付 链接，为用户提供更多支付选择，直接挑战了苹果的支付垄断地位。 面对外界压力，苹果于5月6日正式提起上诉，试图撤销此前被强制要求允许开发者在应用内添加外部 ...

加强研发投入，打破国外技术垄断。24 年研发投入9754 万元，同比+11.9%。在光通信领域，公司聚焦 中高端光学元件，尤其是WSS 核心光学元件衍射光栅；在激光行业，公司围绕超短脉冲激光、高功率 激光、深紫外激光，与国内外主要激光器厂家紧密合作，同步进行先进晶体、精密光学和激光器件的研 发投入和新品推出，打破了关键核心技术的国外垄断。 投资建议：考虑下游激光器市场仍处于缓慢复苏阶段，我们适当调整盈利预期，预计公司2025-27 年归 母净利润为2.7/3.3/4.1 亿元（此前对应2025-26 年为2.7/3.3 亿元），对应PE 估值61/50/41 倍，维持"买 入"评级。 风险提示事件：激光器市场景气度下行的风险；光通信行业增长不及预期；新品研发不及预期；研报使 用的信息更新不及时风险。 事件：公司发布2024 年及25Q1 业绩： 1）2024：收入8.8 亿元，同比+12.0%；归母净利润2.2 亿元，同比+4.7%；扣非归母净利润2.2 亿元，同 比+11.2%。毛利率53.8%，同比-2.4pct；净利率25.9%，同比-1.1pct。 2）25Q1：收入2.4 亿元，同比+15.2%；归 ...

Core Viewpoint - The recent antitrust penalties against three pharmaceutical companies in China highlight the exploitation of market concentration to inflate drug prices, particularly during the COVID-19 pandemic, raising concerns about unethical practices in the industry [1][7]. Group 1: Antitrust Case Details - Tianjin Municipal Market Supervision Administration imposed a total fine of 326 million yuan on Tianjin Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, and Xianju Pharmaceutical for colluding to manipulate the price of Dexamethasone Sodium Phosphate [1][7]. - The price of Dexamethasone Sodium Phosphate surged from approximately 7,900 yuan per kilogram in November 2021 to 45,000 yuan per kilogram by November 2023, indicating a significant price manipulation [1][5]. Group 2: Market Dynamics - The concentration of market competition is a key factor enabling these companies to control raw material and formulation prices, with the three companies holding four out of eight approved production licenses for Dexamethasone Sodium Phosphate [3][4]. - The demand for Dexamethasone Sodium Phosphate injections increased significantly during the pandemic, allowing companies to profit even as costs rose, leading to further price hikes [4][5]. Group 3: Regulatory Environment - The Chinese government has adopted a "zero tolerance" approach towards monopolistic behaviors in the pharmaceutical sector, as evidenced by the total fines of 1.772 billion yuan for antitrust cases in 2023 [7]. - The ongoing normalization of national medical insurance procurement and the enhancement of antitrust regulatory frameworks are expected to reduce the gray areas of vertical monopolies in the pharmaceutical industry [7].

Core Viewpoint - The article highlights the issue of pharmaceutical companies engaging in price-fixing and monopolistic practices, leading to significant price increases for essential medications, particularly the drug "新斯的明" (Neostigmine), which has seen price hikes of 11 to 21 times due to collusion among three companies [2][3][19]. Group 1: Price Manipulation and Regulatory Actions - Xianju Pharmaceutical was fined 195 million yuan for its involvement in a monopoly case related to dexamethasone phosphate raw materials [1]. - The price of Neostigmine injection surged from 2-3 yuan to over 30 yuan per unit, representing an increase of over 10 times [6][10]. - The sales revenue of Neostigmine in public medical institutions exceeded 3 billion yuan in 2020, with a year-on-year growth of 446.81% [10]. Group 2: Impact on Patients and Market Dynamics - Neostigmine is critical for treating myasthenia gravis and has no alternative medications, making its price increase particularly harmful to patients [4][14][16]. - The drug was included in the National Shortage Drug List, which pharmaceutical companies used as a pretext for price hikes [11][13]. - By the end of 2024, Neostigmine was included in the tenth batch of centralized procurement, with prices dropping to below 1 yuan per unit, exposing the previous price inflation as unjustified [17][18]. Group 3: Monopolistic Practices and Legal Framework - The collusion among the three companies involved not only price increases but also market division to maintain their market shares [19][20]. - The penalties for monopolistic behavior have historically been light, with the revised Anti-Monopoly Law in 2022 introducing personal liability for executives, marking a shift in enforcement [5][29][35]. - The fines imposed on companies often do not reflect the substantial illegal profits gained from monopolistic practices, leading to calls for stricter enforcement and higher penalties [27][30].

Core Viewpoint - Google is prioritizing its own AI service, Gemini, over third-party AI companies by restricting access to key search result data, despite previous openness to some AI firms [1][2]. Group 1: Google's AI Strategy - Google has confirmed that it retains critical functionalities for its AI service, Gemini, while allowing limited access to its search results for other AI companies [1]. - The company has launched a "traceability" service within its Vertex AI platform, enabling AI models to utilize Google search results to enhance response accuracy [1]. - Google has invested approximately $3 billion in AI startup Anthropic, which has sought additional access to Google search data for its Claude model [2]. Group 2: Legal and Regulatory Context - The U.S. Department of Justice (DOJ) has proposed that Google share extensive data used to build search results, aiming to foster competition in the AI sector [2][3]. - A federal judge previously ruled that Google illegally monopolized the online search market, and hearings are ongoing to determine necessary corrective actions [2]. - Google's search head, Liz Reed, criticized the DOJ's data-sharing proposal as overly broad and a potential privacy violation, estimating it could require reallocating up to 2,000 engineers to compliance tasks [3]. Group 3: Competitive Landscape - Meta's CEO Mark Zuckerberg has indicated that Meta's AI models utilize Google services for information traceability, highlighting Google's competitive position in the AI space [3]. - OpenAI attempted to negotiate access to Google's search index but was denied, illustrating the competitive barriers in the industry [3].

对于这一重大信息，投资者质疑仙琚制药存在延迟披露问题。 仙琚制药在4月23日披露的2024年年报中进行了披露，并确认了预计负债和相关损失。 而早在4月21日，仙琚制药就收到了相关部门拟处罚的告知书。对此，仙琚制药没有进行单独披露。 受上述事项影响，2024年，仙琚制药归属于母公司股东的净利润(简称"归母净利润")同比下降近30%， 为3.97亿元。这已是公司归母净利润连续两年快速下降。 仙琚制药是一家老牌制药企业，公司的发展愿景为"成为全世界前十名的甾体药物供应商"。 不过，公司经营业绩处于止步不前状态。2020年至2024年的五个年度，公司营业收入在40亿元左右波 动，增长乏力。 垄断原料药被罚没近2亿 垄断原料药，仙琚制药（002332）(002332.SZ)收到了大额罚单。 5月5日晚，仙琚制药发布公告称，4月30日，公司收到天津市市场监督管理委员会下发的《行政处罚决 定书》，公司因涉及垄断地塞米松磷酸钠原料药价格，被罚没约1.95亿元。 在2024年业绩说明会上，多名参会投资者质疑"收到近2亿元的处罚通知，不公告，暗箱操作"。对此， 仙琚制药相关负责人没有作出具体解释。 仙琚制药在公告中表示，本次行政 ...